1. Scrip

Roche Hit By Surprising Tecentriq Miss In TNBC

Has Improved Survival With Nab-Paclitaxel But Not With Paclitaxel

 
• By Kevin Grogan

Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.

Roche tower
Roche HQ: Will Swiss major rue IMpassion131 study miss? • Source: Shutterstock

Roche Holding AG’s dominance in immunotherapy for triple-negative breast cancer (TNBC) has been loosened on the surprising news that a combination of its PD-L1 inhibitor Tecentriq and paclitaxel has failed a late-stage trial.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D